- Home
- INMB vs GSIW Comparison
INMB vs GSIW Comparison
Compare INMB & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INMB | GSIW |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 28.6M |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | INMB | GSIW |
|---|---|---|
| Price | $1.13 | $16.70 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.40 | N/A |
| AVG Volume (30 Days) | 427.8K | ★ 439.7K |
| Earning Date | 03-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000.00 | N/A |
| Revenue This Year | $264.29 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 257.14 | N/A |
| 52 Week Low | $1.10 | $0.05 |
| 52 Week High | $11.64 | $36.90 |
Technical Indicators
Market Signals| Indicator | INMB | GSIW |
|---|---|---|
| Relative Strength Index (RSI) | 37.50 | 58.81 |
| Support Level | N/A | $15.28 |
| Resistance Level | $1.48 | $36.90 |
| Average True Range (ATR) | 0.08 | 1.55 |
| MACD | -0.01 | -0.79 |
| Stochastic Oscillator | 10.61 | 11.43 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.